Drugs & Targets FDA grants accelerated approval to Yescarta for relapsed or refractory follicular lymphoma March 12, 2021Vol.47 No.10
Drugs & Targets Health Canada approves Keytruda as first-line treatment for adults with MSI-H or dMMR colorectal cancer March 12, 2021Vol.47 No.10
Drugs & Targets Surface Oncology, Merck to collaborate on immuno-oncology study evaluating SRF388, targeting IL-27 + Keytruda (pembrolizumab) in solid tumors March 12, 2021Vol.47 No.10
Drugs & Targets Syapse expands strategic collaboration with Pfizer, focusing on RWE March 12, 2021Vol.47 No.10
Conversation with The Cancer Letter Not for sale: Fox Chase Cancer Center March 05, 2021Vol.47 No.09By Paul Goldberg
Three companies withdraw cancer indications for PD-1/PD-L1 drugs in FDA’s “industry-wide evaluation” March 05, 2021Vol.47 No.09By Paul Goldberg
NASEM: Reduce cancer drug waste by reformulating development, payments, dosing March 05, 2021Vol.47 No.09By Alexandria Carolan
In Brief Sarah Hawley named associate director education, training programs at UMich Rogel Cancer Center March 05, 2021Vol.47 No.09
In Brief Lilli Petruzzelli named SVP of early clinical development at Genentech’s gRED March 05, 2021Vol.47 No.09
